ドライパウダー吸入器:医療機器パイプライン製品状況2021

◆英語タイトル:Dry Powder Inhaler Devices - Medical Devices Pipeline Product Landscape, 2021
◆商品コード:GD21JU017
◆発行会社(リサーチ会社):GlobalData
◆発行日:2021年6月
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥460,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥920,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD12,000 ⇒換算¥1,380,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グローバルデータ社の本調査レポートでは、ドライパウダー吸入器の世界市場について調査し、イントロダクション、開発中製品、企業別分析、企業/製品概要、最近の動向などを掲載しています。

・イントロダクション
・開発中のドライパウダー吸入器
・ドライパウダー吸入器の企業別分析
・ドライパウダー吸入器の企業/製品概要
・最近のドライパウダー吸入器動向
【レポートの概要】

Dry Powder Inhaler Devices – Medical Devices Pipeline Product Landscape, 2021
Summary

GlobalData’s Medical Devices sector report, “Dry Powder Inhaler Devices – Medical Devices Pipeline Product Landscape, 2021″ provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to Buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Dry Powder Inhaler Devices Overview
3 Products under Development
3.1 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development
3.2 Dry Powder Inhaler Devices – Pipeline Products by Territory
3.3 Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path
3.4 Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date
3.5 Dry Powder Inhaler Devices – Ongoing Clinical Trials
4 Dry Powder Inhaler Devices – Pipeline Products under Development by Companies
4.1 Dry Powder Inhaler Devices Companies – Pipeline Products by Stage of Development
4.2 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development
5 Dry Powder Inhaler Devices Companies and Product Overview
5.1 Adamis Pharmaceuticals Corp Company Overview
5.2 Advent Pharmaceuticals Pty Ltd Company Overview
5.3 Aespira Ltd. Company Overview
5.4 AKELA Pharma Inc. (Inactive) Company Overview
5.5 AstraZeneca Plc Company Overview
5.6 Bayer AG Company Overview
5.7 Cambridge Healthcare Innovations Ltd Company Overview
5.8 Circassia Group Plc Company Overview
5.9 Creare LLC Company Overview
5.10 Eli Lilly and Co Company Overview
5.11 GlaxoSmithKline Plc Company Overview
5.12 Glenmark Pharmaceuticals Ltd Company Overview
5.13 Hovione Technology Ltd Company Overview
5.14 Iconovo AB Company Overview
5.15 Liquidia Technologies Inc Company Overview
5.16 Lupin Pharmaceuticals Inc Company Overview
5.17 MannKind Corp Company Overview
5.18 Monash University Company Overview
5.19 Nektar Therapeutics Company Overview
5.20 Ology Bioservices Inc Company Overview
5.21 OPKO Health Inc Company Overview
5.22 OtiTopic Inc Company Overview
5.23 Pharmaxis Ltd Company Overview
5.24 Quench Medical Inc Company Overview
5.25 Respira Therapeutics Inc Company Overview
5.26 Respirent Pharmaceuticals Co Ltd Company Overview
5.27 Sandoz International GmbH Company Overview
5.28 Sheffield Hallam University Company Overview
5.29 Shin Nippon Biomedical Laboratories Ltd Company Overview
5.30 Spyryx Biosciences Inc Company Overview
5.31 Sun Pharma Advanced Research Company Ltd Company Overview
5.32 United Therapeutics Corp Company Overview
5.33 University of Kansas Company Overview
5.34 University of Sydney Company Overview
5.35 University of Texas Medical Branch at Galveston Company Overview
5.36 Vectura Group Plc Company Overview
5.37 Verona Pharma Plc Company Overview
5.38 Virginia Commonwealth University Company Overview
6 Dry Powder Inhaler Devices- Recent Developments
6.1 Jun 08, 2021: MannKind at the Lytham Partners Summer 2021 Investor Conference
6.2 May 06, 2021: Nektar Therapeutics Reports First Quarter 2021 Financial Results
6.3 Apr 28, 2021: Teva Reports First Quarter 2021 Financial Results
6.4 Apr 27, 2021: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed
6.5 Apr 12, 2021: Orion publishes Interim Report for January–March 2021 on Tuesday 27 April 2021
6.6 Apr 06, 2021: GSK announces Dr Anne Beal to join the Board as Non-Executive Director
6.7 Mar 29, 2021: Chiesi and Hephai join forces to develop AI educational tool to improve inhaler use
6.8 Mar 25, 2021: Decisions taken by Orion Annual General Meeting on 25 March 2021
6.9 Mar 22, 2021: Novartis appoints Karen Hale as Chief Legal Officer
6.10 Mar 19, 2021: GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women’s Cancer
6.11 Mar 10, 2021: MannKind Corporation to Participate in Oppenheimer’s 31st Annual Healthcare Conference
6.12 Mar 03, 2021: Change to the Notice of Orion Annual General Meeting
6.13 Mar 02, 2021: MannKind to Participate in H.C. Wainwright Global Life Sciences Conference
6.14 Mar 01, 2021: Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference
6.15 Feb 18, 2021: MannKind to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
6.16 Feb 18, 2021: OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results
6.17 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021
6.18 Feb 18, 2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
6.19 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
6.20 Feb 11, 2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
6.21 Feb 08, 2021: GSK Consumer Health Pakistan appoints Farhan Muhammad Haroon as CEO
6.22 Feb 02, 2021: Jim Fitterling elected to 3M board of directors
6.23 Jan 26, 2021: Adamis Pharmaceuticals provides update on its us compounding business
6.24 Jan 12, 2021: Vectura Group: Trading update
6.25 Jan 06, 2021: Nektar Therapeutics’ President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
6.26 Jan 04, 2021: MannKind to Participate in H.C. Wainwright Bioconnect 2021 Conference
6.27 Nov 26, 2020: GLAXOSMITHKLINE: EMTN supplementary prospectus
6.28 Oct 23, 2020: Orion starts biologic joint venture in China
6.29 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
6.30 Jul 10, 2020: Operation Clean Sweep
6.31 Jul 09, 2020: Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer

List of Tables
Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Dry Powder Inhaler Devices - Pipeline Products by Territory
Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Dry Powder Inhaler Devices - Ongoing Clinical Trials
Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
APC-4000- Fluticasone DPI - Product Status
APC-4000- Fluticasone DPI - Product Description
Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
g60 Dry Powder Inhaler - Product Status
g60 Dry Powder Inhaler - Product Description
Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
resQhaler - Product Status
resQhaler - Product Description
AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Fentanyl TAIFUN Inhaler - Product Status
Fentanyl TAIFUN Inhaler - Product Description
AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
Duaklir Genuair Metered Dose Inhaler - Product Status
Duaklir Genuair Metered Dose Inhaler - Product Description
Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
Ciprofloxacin Dry Powder Inhaler - Product Status
Ciprofloxacin Dry Powder Inhaler - Product Description
Cambridge Healthcare Innovations Ltd Pipeline Products & Ongoing Clinical Trials Overview
aeolus Dry-Powder Inhaler - Product Status
aeolus Dry-Powder Inhaler - Product Description
Circassia Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Tiotropium bromide DPI - Product Status
Tiotropium bromide DPI - Product Description
Creare LLC Pipeline Products & Ongoing Clinical Trials Overview
Intranasal Dry Powder Inhaler - Product Status
Intranasal Dry Powder Inhaler - Product Description
Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
Nasal Glucagon Delivery System - Product Status
Nasal Glucagon Delivery System - Product Description
GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
Gemini Multi-Dose Combination Inhaler - Product Status
Gemini Multi-Dose Combination Inhaler - Product Description
Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview
Tiogiva - Product Status
Tiogiva - Product Description
Hovione Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview
Papillon - Product Status
Papillon - Product Description

List of Figures
Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Dry Powder Inhaler Devices - Pipeline Products by Territory
Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Dry Powder Inhaler Devices - Ongoing Clinical Trials

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ドライパウダー吸入器:医療機器パイプライン製品状況2021]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆